BioNTech (BNTX) Company Report

Analyst Coverage

Research analysts who have asked questions during BioNTech earnings calls.

Daina Graybosch

Leerink Partners

8 questions for BNTX

Also covers: AFMD, CGEN, FATE +6 more

Tazeen Ahmad

Bank of America

8 questions for BNTX

Also covers: ACAD, ALNY, APLS +23 more

Yaron Werber

TD Cowen

8 questions for BNTX

Also covers: ALEC, AMGN, ARGX +15 more

Cory Kasimov

Evercore ISI

6 questions for BNTX

Also covers: ALNY, BBIO, BMRN +7 more

Mohit Bansal

Wells Fargo & Company

6 questions for BNTX

Also covers: ABBV, AMGN, BMRN +16 more

Terence Flynn

Morgan Stanley

6 questions for BNTX

Also covers: ABBV, AMGN, ARVN +17 more

Jessica Fye

JPMorgan Chase & Co.

4 questions for BNTX

Also covers: ALKS, ALNY, AMRN +23 more

Akash Tewari

Jefferies

3 questions for BNTX

Also covers: ALKS, APLS, ARGX +15 more

Asad Haider

Goldman Sachs

3 questions for BNTX

Also covers: ABBV, BMY, JNJ +5 more

Evan Seigerman

BMO Capital Markets

3 questions for BNTX

Also covers: ABBV, AMGN, ARVN +15 more

Jay Olson

Oppenheimer & Co. Inc.

3 questions for BNTX

Also covers: ACAD, AMGN, BIIB +24 more

Asthika Goonewardene

Truist Securities

2 questions for BNTX

Also covers: ALLO, AUTL, CGEN +10 more

Chris

Morgan Stanley

2 questions for BNTX

Also covers: GILD, MRNA, REGN +1 more

Harry Gillis

Berenberg

2 questions for BNTX

Also covers: QGEN

Jarrod

Citigroup

2 questions for BNTX

Kari

Truist

2 questions for BNTX

Malcolm Hoffman

BMO Capital Markets

2 questions for BNTX

Also covers: ABCL, ACAD, BMY +2 more

Manoj

Jefferies

2 questions for BNTX

Also covers: ARVN, IONS

Manoj Eradath

Jefferies LLC

2 questions for BNTX

Also covers: ZYME

Nic Jennings

Goldman Sachs

2 questions for BNTX

Chris Shibutani

Goldman Sachs Group, Inc.

1 question for BNTX

Also covers: ABBV, ALKS, BMY +11 more

Eliana Merle

UBS

1 question for BNTX

Also covers: ALNY, APLS, ARVN +17 more

John Newman

Canaccord Genuity Group Inc.

1 question for BNTX

Also covers: ALLO, ATRA, DCTH +4 more

Joshua Chazaro

Evercore ISI

1 question for BNTX

Joshua Tassaro

Evercore ISI

1 question for BNTX

Manos Mastorakis

Deutsche Bank

1 question for BNTX

Also covers: ARGX, GLPG

Nishan Sarna

Citigroup

1 question for BNTX

Simon Baker

Redburn Atlantic

1 question for BNTX

Also covers: AUTL, AZN, GILD +5 more

Suzanne van Voorthuizen

Kempen & Co

1 question for BNTX

Also covers: ARGX, GMAB, HOOK +3 more

Yifeng Liu

HSBC

1 question for BNTX

Also covers: GMAB

Latest news

Recent press releases and 8-K filings for BNTX.

BioNTech Announces Leadership Transition and 2026 Outlook

BNTX

CEO Change

Guidance Update

New Projects/Investments

BioNTech ended 2025 in a strong financial position with more than EUR 17 billion in cash equivalents and securities.
For 2026, the company anticipates lower Comirnaty (COVID-19 vaccine) revenues compared to 2025, with adjusted R&D expenses projected between EUR 2.2 billion and EUR 2.5 billion and adjusted SG&A expenses between EUR 700 million and EUR 800 million.
CEO Ugur Sahin and Co-Founder Öezlem Türeci will transition by the end of 2026 to lead a new independent company focused on next-generation mRNA innovations, in which BioNTech will hold a minority stake.
The oncology pipeline is advancing, with multiple late-stage event-driven readouts anticipated in 2026 and a Phase 3 trial for BNT324 in metastatic castration-resistant prostate cancer expected to begin recruitment soon.

2 days ago

Transcript

BioNTech Reports Strong 2025 Financials, Provides 2026 Guidance, and Announces Leadership Transition

BNTX

Earnings

Guidance Update

Management Change

BioNTech reported total revenues of EUR 2.9 billion for 2025, exceeding its raised guidance, and concluded the year with a strong financial position of EUR 17.2 billion in cash equivalents and securities.
The company issued 2026 revenue guidance of EUR 2 billion to EUR 2.3 billion, anticipating lower COVID-19 vaccine revenues but continued contributions from the BMS collaboration.
BioNTech is significantly advancing its oncology pipeline, expecting six late-stage trial readouts in 2026 and aiming to have eight global phase III trials running by year-end, focusing on assets like pumitamig and ADCs.
CEO Ugur Sahin and CMO Özlem Türeci will transition from their roles by the end of 2026, with a search for new leadership underway, while a new company is being discussed for next-generation mRNA innovation, in which BioNTech will hold a minority stake.

2 days ago

Transcript

BioNTech Announces Q4 and Full Year 2025 Results and 2026 Guidance

BNTX

Earnings

Guidance Update

Management Change

BioNTech reported Full Year 2025 IFRS Total Revenues of €2,870 million, exceeding its guidance of €2,600 - €2,800 million.
The company maintained a strong financial position, ending 2025 with €17.2 billion in cash, cash equivalents, and securities.
For Full Year 2026, BioNTech projects non-IFRS Total Revenues between €2,000 million and €2,300 million.
A CEO and CMO transition is expected by the end of 2026 as part of a strategic focus to become a multi-product company by 2030.
The company anticipates a catalyst-rich 2026 with multiple expected milestones, including late-stage trial readouts, Phase 3 trial initiations, and BLA submissions for its oncology pipeline.

2 days ago

Presentation

BioNTech Founders to Transition to New Company, Reports 2025 Financials and 2026 Guidance

BNTX

Management Change

Guidance Update

New Projects/Investments

BioNTech founders Ugur Sahin and Özlem Türeci will transition by the end of 2026 to lead a new independent company focused on next-generation mRNA innovations, with BioNTech holding a minority stake and contributing related rights and mRNA technologies but no capital.
For full year 2025, BioNTech reported total revenues of EUR 2.9 billion and an adjusted non-IFRS net loss of EUR 117 million, ending the year with EUR 17.2 billion in cash equivalents.
The company provided full year 2026 revenue guidance in the range of EUR 2 billion to EUR 2.3 billion, anticipating lower COVID-19 vaccine revenues compared to 2025.
BioNTech expects six readouts from late-stage trials in 2026, including interim analyses for FixVac (HPV 16-positive head and neck cancer), TPAM (HR-positive HER2-low breast cancer and endometrial cancer), and gotistobart (squamous non-small cell lung cancer).

2 days ago

Transcript

BioNTech Announces Q4 and Full Year 2025 Financial Results and 2026 Guidance

BNTX

Earnings

Guidance Update

Management Change

BioNTech reported full year 2025 revenues of €2.9 billion and a net loss of €1.1 billion, with an adjusted net loss of €0.1 billion.
The company maintained a strong financial position with €17.2 billion in cash, cash equivalents, and security investments as of December 31, 2025.
For 2026, BioNTech expects total revenues between €2.0 billion and €2.3 billion, adjusted R&D expenses between €2.2 billion and €2.5 billion, and adjusted SG&A expenses between €700 million and €800 million.
Co-founders Ugur Sahin and Özlem Türeci will transition from management by the end of 2026 to establish an independent company focused on next-generation mRNA innovations.
BioNTech anticipates a catalyst-rich 2026 with six late-stage data readouts across its immunomodulator, antibody-drug conjugate, and mRNA cancer immunotherapy programs.

2 days ago

6-K

BioNTech Announces Plan for Co-Founders to Lead New mRNA Innovation Company

BNTX

Management Change

New Projects/Investments

BioNTech SE announced plans for its co-founders, Prof. Ugur Sahin and Prof. Özlem Türeci, to establish and lead an independent biotechnology company focused on next-generation mRNA innovations.
BioNTech plans to contribute related rights and mRNA technologies to the new company in exchange for a minority stake and other considerations such as milestones and royalties.
The co-founders will transition to the management of their new company by the end of 2026.
BioNTech will sharpen its strategic focus on its growing late-stage clinical pipeline and aims to become a multi-product company by 2030.
Binding agreements for this plan are expected to be signed by the end of the first half of 2026.

2 days ago

6-K

BioNTech Outlines 2026 Strategy and Clinical Trial Expansion

BNTX

New Projects/Investments

Guidance Update

BioNTech outlined its 2026 strategy at the J.P. Morgan Healthcare Conference, including plans to initiate six additional Phase 3 clinical trials this year.
The company currently has more than 25 ongoing Phase 2 or 3 oncology trials and held approximately 17.2 billion euros in cash as of December 2025, positioning it to fund at least 17 late-stage data readouts expected by 2030.

Feb 25, 2026, 2:00 PM

Press Release

BioNTech Forms Major Partnership for Bispecific Antibody BNT327

BNTX

New Projects/Investments

M&A

The U.S. bispecific antibodies market is projected to grow from an estimated $11.78 billion in 2024 to $271.95 billion by 2033, at a 40.1% Compound Annual Growth Rate (CAGR) from 2025 to 2033.
This market expansion is driven by the rising burden of cancer and autoimmune diseases, demand for precise therapies, FDA approvals, and increased investment in research and development.
In June 2025, BioNTech partnered with Bristol Myers Squibb in a deal valued at up to $11.1 billion for the co-development and co-commercialization of its investigational bispecific antibody BNT327. This deal includes $1.5 billion upfront, $2 billion in guaranteed payments, and up to $7.6 billion in additional development, regulatory, and commercial milestones.

Jan 21, 2026, 9:52 AM

Press Release

BioNTech Provides Strategic Business Update and 2026 Focus Areas

BNTX

Guidance Update

New Projects/Investments

M&A

BioNTech reported a preliminary, unaudited cash balance of €17.2 billion as of December 31, 2025, and increased its 2025 revenue guidance on November 3, 2025, to €2,600 - €2,800 million.
For 2026, the company anticipates a modest decline in Comirnaty revenues compared to 2025 and does not expect to recognize revenues from oncology product sales.
BioNTech has 25 ongoing Phase 2 & 3 oncology trials and expects a catalyst-rich 2026 with multiple late-stage trial readouts, Phase 3 trial initiations, and a Biologics License Application (BLA) submission for Trastuzumab pamirtecan.
The company aims to build a multi-product oncology company by 2030, targeting 17+ late-stage / pivotal trial readouts through 2030+ to become a diversified, multi-product global immunotherapy powerhouse.

Jan 13, 2026, 11:18 PM

6-K

BioNTech Reports Strong 2025 Performance and Oncology Pipeline Momentum

BNTX

Guidance Update

New Projects/Investments

M&A

BioNTech reported a strong financial position with €17.2 billion in cash, cash equivalents, and securities as of December 31, 2025.
The company increased its 2025 revenue guidance on November 3, 2025, to a range of €2,600 - €2,800 million.
BioNTech has a robust oncology pipeline with over 25 Phase 2 & 3 oncology trials ongoing in 2025 and 15 Phase 2 & 3 readouts expected in 2026-2027.
While maintaining COVID-19 vaccine market leadership with over 50% share in fall 2025, the company anticipates a modest decline in Comirnaty revenues in 2026.